MEGAN JONES: Open Payments
NPI 1215635966 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,636 in 80 payments from 22 companies in 2025. Trend: 2023 $295 · 2024 $2,080 · 2025 $1,636
Food & beverage: $1,636
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $352 |
| Lilly USA, LLC | 11 | $233 |
| ABBVIE INC. | 8 | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $137 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $89 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| PFIZER INC. | 4 | $72 |
| AstraZeneca Pharmaceuticals LP | 3 | $66 |
| Exact Sciences Corporation | 3 | $54 |
| Dexcom, Inc. | 3 | $48 |
Products named: MOUNJARO, Rybelsus, JARDIANCE, Ozempic, XIFAXAN, VRAYLAR, CAPLYTA, Dexcom G6 Transmitter.
Industry payments across MD — which companies pay providers there.
